| Previous close | 0.9500 |
| Open | 0.9500 |
| Bid | 0.8000 |
| Ask | 1.0000 |
| Strike | 7.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.8500 - 0.9500 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.4k |
Simply Wall St.Most Shareholders Will Probably Agree With BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) CEO Compensation
Key Insights BioCryst Pharmaceuticals' Annual General Meeting to take place on 12th of June Salary of US$665.6k is part...
GlobeNewswireBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., June 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees stock options to purchase an aggregate of 74,875 shares, and restricted stock units (RSUs) covering an aggregate of 39,050 shares, of BioCryst common stock. The options and RSUs were granted as of May 31, 2024, as inducements material to each employee entering into employment
- GlobeNewswire
BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment
Additional results from largest body of evidence on attenuated androgen use in HAE reinforce need for access to safer and more tolerable HAE prophylaxis optionsRESEARCH TRIANGLE PARK, N.C., June 02, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence showing that patients with hereditary angioedema (HAE) who have normal C1-inhibitor (HAE-nC1-INH) level and function had a reduction in monthly attack rates after starting oral, once-daily O
